drug_type
RELEVANT_DRUG
intervention_type
Genetically modified cellular immunotherapy (CAR-modified CIK/T cells)
drug_description
An allogeneic cytokine-induced killer (CIK) cell therapy genetically engineered via transposon to express a CD19-directed chimeric antigen receptor (anti-CD19 scFv with CD3ζ signaling and CD28/OX40 costimulation) for treatment of relapsed/refractory CD19+ B-cell malignancies (NHL, CLL).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic cytokine-induced killer (CIK) T cells engineered via transposon to express a CD19-targeted CAR with CD3ζ signaling and CD28/OX40 costimulation. CAR engagement of CD19 on B cells triggers T/CIK activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxicity to eliminate CD19+ malignant B cells.
drug_name
CARCIK-CD19
nct_id_drug_ref
NCT05869279